Table 1 Patient characteristics
Characteristics | Total | AKI [ABW] | AKI [IBW] | P-value |
|---|---|---|---|---|
n = 569 | n = 153 | n = 140 | ||
Age, years | 69 (59–78) | 69 (59–78) | 69 (59–78) | 0.998 |
Male sex, No. | 305 (53.6%) | 89 (58.2%) | 89 (63.6%) | 0.344 |
Body weight, kg | 57 (48–66) | 59 (52–70) | 58 (50–68) | 0.293 |
Height, cm | 158 (150–166) | 160 (152–167) | 160 (154–167) | 0.452 |
BMI, kg/m2 | 22.5 (19.7–25.3) | 23.6 (21.1–26.6) | 23.0 (20.1–25.5) | 0.082 |
Infection site, No. | 0.999 | |||
CNS | 6 (1.0%) | 0 (0%) | 0 (0%) | |
Thorax | 128 (22.5%) | 37 (24.2%) | 33 (23.6%) | |
Abdomen | 301 (52.9%) | 72 (47.1%) | 64 (45.7%) | |
Head and neck | 25 (4.4%) | 1 (0.7%) | 1 (0.7%) | |
Soft tissue | 32 (5.6%) | 14 (9.2%) | 13 (9.3%) | |
UTI | 25 (4.4%) | 2 (1.3%) | 2 (1.4%) | |
CR-BSI | 5 (0.9%) | 4 (2.6%) | 3 (2.1%) | |
Other | 49 (8.6%) | 23 (15.0%) | 24 (17.1%) | |
Unknown premorbid creatinine, No. | 254 (44.6%) | 58 (37.9%) | 54 (38.6%) | |
Premorbid creatinine, mg/dL | 0.75 (0.60–0.96) | 0.82 (0.63–1.09) | 0.83 (0.69–1.18) | 0.756 |
Comorbidities, No. | ||||
CKD | 158 (27.8%) | 58 (61.1%) | 54 (61.4%) | 0.810 |
IHD | 53 (9.3%) | 18 (11.8%) | 14 (10.0%) | 0.629 |
CHF | 50 (8.8%) | 21 (13.7%) | 16 (11.4%) | 0.554 |
Hypertension | 273 (48.0%) | 84 (54.9%) | 74 (52.9%) | 0.726 |
Arrhythmia | 57 (10.0%) | 23 (15.0%) | 20 (14.3%) | 0.857 |
COPD | 32 (5.6%) | 6 (3.9%) | 7 (5.0%) | 0.654 |
CVA | 62 (10.9%) | 21 (13.7%) | 16 (11.4%) | 0.554 |
DM | 145 (25.5%) | 47 (30.7%) | 43 (30.7%) | 0.999 |
Immune dysfunction | 171 (30.0%) | 54 (35.3%) | 51 (36.4%) | 0.840 |
Hepatic disease | 53 (9.3%) | 18 (11.8%) | 18 (12.9%) | 0.776 |
Aminoglycoside use | 8 (1.4%) | 3 (2.0%) | 3 (2.1%) | 0.913 |
Vancomycin use | 139 (24.4%) | 55 (36.0%) | 49 (35.0%) | 0.866 |
Septic shock | 247 (43.4%) | 87 (56.9%) | 81 (57.9%) | 0.864 |
ISTH DIC | 125 (22.5%) | 55 (36.7%) | 54 (39.4%) | 0.632 |
SOFA score | 7 (4–9) | 9 (7–11) | 10 (7–12) | 0.617 |
SAPS II | 50 (39–62) | 63 (52–77) | 64 (51–77) | 0.760 |
Urinary diagnosis of AKI, No. | 0.852 | |||
Stage 1 | 51 (9.0%) | 45 (7.9%) | ||
Stage 2 | 38 (6.7%) | 32 (5.6%) | ||
Stage 3 | 64 (11.2%) | 63 (11.1%) | ||
Mechanical ventilation, No. | 462 (81.2%) | 139 (90.9%) | 124 (88.6%) | 0.521 |
Days of mechanical ventilation | 7 (5–12) | 8 (6–15) | 9 (6–16) | 0.957 |
Days of ICU stay | 8 (5–12) | 10 (7–16) | 10 (6–16) | 0.862 |
90-day mortality | 19.0% | 38.4% | 42.3% | 0.624 |